QNTM Rasio cepet Quantum BioPharma Ltd

Quantum BioPharma Ltd (QNTM) is developing a biotechnology health business, aiming for dominance in narrow niches through innovation. However, the dilution of strategic priorities between AI and cannabinoids weakens its competitive advantages, creating risks. The current metric stands at 1.24. This chart illustrates the price action of the company, which is integrating green chemistry principles and ethical management into its processes.

This metric is calculated as the ratio of cash and accounts receivable to current liabilities, completely excluding low-liquidity inventory. Amidst a shifting business model and high R&D expenditures at Quantum BioPharma Ltd (QNTM), the quick ratio allows investors to assess the company's ability to settle debts without liquidating assets, signaling potential risks of cash flow gaps.